skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Genetic and pharmacologic manipulation of vacuolar ATPase: Effects on zymogen activation in pancreatic acini

Original Research

(2071) Views  (736) Full article downloads

Authors: Thomas Kolodecik, Fred Gorelick, Edwin Thrower

Published Date November 2009 Volume 2009:1(Default) Pages 1 - 11
DOI: http://dx.doi.org/10.2147/OAAP.S7252

Thomas Kolodecik1,3, Fred Gorelick1–3, Edwin Thrower1,3

1Department of Internal Medicine, Section of Digestive Diseases, 2Department of Cell Biology, Yale University School of Medicine, New Haven, CT, USA; 3Veterans Administration Connecticut Healthcare, West Haven, CT, USA

Abstract: Premature activation of inactive digestive enzymes (or zymogens) within the pancreatic acinar cell is an initiating event in acute pancreatitis (AP). We have found that this response depends on the assembly and activation of an adenosine triphosphate (ATP)-dependent proton pump, the vacuolar ATPase (vATPase). Previously, we have shown that the classic vATPase inhibitors concanamycin and bafilomycin can inhibit zymogen activation induced experimentally by high doses of the cholecystokinin orthologue, cerulein (CER) in isolated acinar cells. Recent studies have questioned the specificity of these inhibitors. In the current study we examine the role of the vATPase in pancreatitis using the newly developed novel vATPase inhibitors lobatomide-B and salicylihalamide-A as well as a genetic approach using siRNA. Both lobatomide-B and salicylihalamide-A inhibited CER-stimulated zymogen (trypsinogen and chymotrypsinogen) activation but had no effect on amylase secretion. Lobatomide-B (0.1 µM) was more potent, reducing activation to baseline levels. Treatment of cells with siRNA specific for the vATPase E-subunit (V1E) significantly decreased V1E expression. V1E siRNA also significantly decreased chymotrypsinogen activation, but not amylase secretion. These studies confirm a role for the vATPase in zymogen activation and demonstrate that the novel and specific inhibitors lobatomide-B and salicylihalamide-A reduce early pancreatitis responses.

Keywords: lobatomide, salicylihalamide, cerulein, siRNA








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
A correlation of haloperidol-induced cognitive deficit with dysfunctional dopamine receptor activity in nonhuman primate
Erratum
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Importance of ivermectin to human onchocerciasis: past, present, and the future
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Eating timing an evolutionary manager of postmodern rumen physiology and health: a review
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University